The FDA approved Rydapt as an initial treatment — used alongside chemotherapy — for acute myeloid leukemia. The drug can also be used to treat several other blood disorders, including aggressive systemic mastocytosis and mast cell leukemia.
Pricing for the drug depends on its indication and dose, Novartis spokeswoman Julie Masow told Reuters. For acute myeloid leukemia patients, the list price for a 14-day treatment is $7,495 and $14,990 for a 28-day treatment length, she said.
More articles on supply chain:
FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.